Oxcia is pleased to announce that the patent for OXC-201, Oxcias potential breakthrough approach for the treatment of IPF (idiopathic pulmonary fibrosis), has now also been approved in Canada. Canada is a key market. Like other IPF markets it is displaying good growth, driven by an ageing population, improved clinical recognition and higher and earlier diagnostic rates. The patent is already approved in the US, Japan and China. The patent application is pending in Europe (EPO – European Patent Organization). The patent is valid until March 2039.
As previously communicated, the EIC (European Innovation Council) awarded Oxcia AB in early 2023 a grant of 2.5 million euros within the EIC-Transition program. The pre-clinical program for OXC-201 is under completion and the first in human clinical Phase 1 trial is due to start in the beginning of 2027.
For more information contact:
Ulrika Warpman Berglund, CEO, Oxcia AB (publ)
Telephone: +46 (0) 73 270 9605
ulrika.warpmanberglund@oxcia.com
Briefly about Oxcia AB
Oxcia’s aim is to improve and extend lives by developing new innovative treatments based on our unique technology platform, O2-DDR. Oxcia AB is a pioneer in oxidative DNA damage and DNA Damage Response (DDR – the processes the body uses to repair the damage that occurs to DNA) with a focus on developing new safe and effective treatments for patients suffering from diseases caused by cancer or inflammation. Oxcia currently has two O2-DDR lead drug candidates, both with the potential to become first-in-class drugs. OXC-101 is in early clinical development as novel cancer therapy. OXC-201 is developed against idiopathic pulmonary fibrosis, and is in the preclinical phase. The portfolio also includes exploratory projects, e.g in psoriasis.
More information about Oxcia is available at www.oxcia.com